Capsida Biotherapeutics to Present New Data on its Wholly Owned Gene Therapy Programs in Genetic Epilepsy and Parkinson’s Disease at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
April 22, 2024
Company unveils Parkinson’s disease associated with GBA mutations (PD-GBA) program; two oral presentations feature new data from Capsida’s wholly owned programs in PD-GBA and genetic epilepsy due to STXBP1 mutations; both programs in IND-enabling studies to support initiation of clinical trials first half of 2025
0 Comments9 Minutes
Capsida Biotherapeutics to Present New Preclinical Data on Potential of Systemically Delivered Next-Generation AAV Therapeutics for Treatment of Genetic Epilepsy
June 2, 2023
Preclinical data show IV administration of a next-generation gene therapy produced dose-dependent replacement of syntaxin-binding protein 1 (STXBP1) throughout the brain, with efficacy predictive of clinical relevance lasting at least 12 months post therapeutic intervention.
0 Comments5 Minutes
AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need
February 23, 2023
AbbVie (NYSE: ABBV) and Capsida Biotherapeutics Inc. ("Capsida") today announced an expanded strategic collaboration to develop genetic medicines for eye diseases with high unmet need. AbbVie's extensive capabilities will be paired with Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability to identify and advance three programs. The collaboration builds upon the neurodegenerative disease partnership announced in 2021.
0 Comments6 Minutes
Capsida Biotherapeutics Presents Data Demonstrating Unique Industry-Leading Technology and Capabilities With Potential to Treat Both Rare and Common Diseases at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 18, 2022
Platform utilizes combinatorial engineering and automation to screen in high-throughput, generating capsids greatly improved over AAV9 in CNS efficiency and specificity. Process development and manufacturing data validate in-house capability to produce highly productive and scalable processes up to 200L.
0 Comments10 Minutes
Capsida Biotherapeutics Presents New Data Validating Potential of Its Targeted, Non-invasive Gene Therapy Platform at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 17, 2022
Preclinical results demonstrate proof-of-concept of early generation AAV-engineered capsid in MPSII pilot program. Data from capsid engineering platform show greater than 100-fold improvement over AAV9 across both infants and juveniles. Top capsid variants show broad protein expression across the primate CNS.
0 Comments9 Minutes
Capsida Appoints Swati Tole, M.D., as Chief Medical Officer
May 12, 2021
Capsida Biotherapeutics Inc., a biotechnology company creating a new class of targeted gene therapies using its next-generation adeno-associated virus (AAV) engineering and cargo development platform, today announced the appointment of Swati Tole, M.D., as the Company’s first chief medical officer.
0 Comments6 Minutes
Capsida Biotherapeutics Debuts with $140 Million of Capital
April 29, 2021
Versant Ventures and Westlake Village BioPartners today announced the emergence from stealth mode of Capsida Biotherapeutics Inc., a biotechnology company using an adeno-associated virus (AAV) engineering and cargo development platform to develop tissue-targeted gene therapies for multiple types of diseases.
0 Comments11 Minutes